Highlights PROCEPT BioRobotics Corporation

Equities

PRCT

US74276L1052

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
65.31 ^USD	+2.85%		+4.01%	+55.83%

05-06	Piper Sandler Adjusts Price Target on PROCEPT BioRobotics to $75 From $67, Maintains Overweight Rating	MT
05-06	PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia	05-06	CI
Procept BioRobotics Shares Rise After Q1 Loss Narrows, Revenue Increases; 2024 Revenue Guidance Revised	05-01	MT
PROCEPT BioRobotics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Reports Q1 Revenue $44.5M, vs. Street Est of $41.7M	05-01	MT
Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024	05-01	CI
PROCEPT BioRobotics Q4 Net Loss Narrows as Revenue Increases	02-28	MT
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Posts Q4 Revenue $43.6M, vs. Street Est of $41.9M	02-27	MT
PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024	02-27	CI
PROCEPT BioRobotics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Procept BioRobotics Reports Preliminary Q4 Revenue, Updates 2023 Guidance	01-08	MT
PROCEPT BioRobotics Corporation Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2023	01-08	CI
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Posts Q3 Revenue $35.1M, vs. Street Est of $33.4M	11-01	MT
PROCEPT BioRobotics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023	11-01	CI
Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer	12/09/23	CI
PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan	22/08/23	CI
Procept BioRobotics, NorthShore University Say Highland Park Hospital Installs AquaBeam System for Prostatic Hyperplasia	16/08/23	MT
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Posts Q2 Revenue $33.1M, vs. Street Est of $30.5M	27/07/23	MT
PROCEPT BioRobotics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	27/07/23	CI
PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023	27/07/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PROCEPT BioRobotics Corporation

Equities

PRCT

US74276L1052

Highlights

Filters